Pathogenesis of bone disease in multiple myeloma: from bench to bedside.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: The authors declare that they have no competing interests. 14. Curr Hematol Malig Rep. 2017 Apr;12(2):109-118. doi: 10.1007/s11899-017-0370-5. An Evidence-Based Approach to Myeloma Bone Disease. Bingham N(1), Reale A(2), Spencer A(3)(4). Author information: (1)Department of Haematology, Alfred Health, Melbourne, Victoria, Australia. (2)Australian Centre for Blood Disorders, Monash University, Melbourne, Victoria, Australia. (3)Department of Haematology, Alfred Health, Melbourne, Victoria, Australia. andrew.spencer@monash.edu. (4)Australian Centre for Blood Disorders, Monash University, Melbourne, Victoria, Australia. andrew.spencer@monash.edu. Multiple myeloma is an incurable clonal plasma cell malignancy characterised by osteolytic bone lesions and the presence of a monoclonal immunoglobulin. The bone disease caused by myeloma is a major cause of morbidity with the related complications of pathological fractures, hypercalcaemia and bone pain affecting both quality of life and patient survival. The osteolytic lesions arise due to an imbalance of osteoclast and osteoblast function, arising from complex interactions between myeloma cells, bone marrow stromal cells and the bone marrow microenvironment. These advances in understanding of the pathophysiology have directly led to improvements in patient management and outcomes. Recent advances in myeloma bone disease are reviewed, including the role of novel and emerging therapies, and evidence-based management strategies for myeloma bone disease are discussed. DOI: 10.1007/s11899-017-0370-5